Işıl Erdoğan Özünal

5PUBLICATIONS
9CO-AUTHORS
HaematologyPharmacogenomicsPredictive and prognostic markersCardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 04, 2023
High-density lipoprotein (HDL) has an impact on myeloma outcome: Lower HDL associates with worse progression-free survival.

Işıl Erdoğan Özünal, Emrah Kılıçaslan, Tayfun Elibol

|Feb 27, 2023
Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?

Ilgın Koçak Göktürk, Işıl Erdoğan Özünal, Alican Göktürk

|Mar 21, 2022
Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma.

Erman Ozturk, Tayfun Elibol, Emrah Kilicaslan

|Oct 20, 2021
Are Hematologic Patients Trojan Horse for COVID-19?

Emrah Kılıçaslan, Işıl Erdoğan Özünal, Tayfun Elibol

|Jul 09, 2021
A Rare Side Effect of Ibrutinib: Tumor Lysis Syndrome.

Erman Ozturk, Isıl Erdogan Ozunal

Pageof 1